Latest Insider Transactions at Longboard Pharmaceuticals, Inc. (LBPH)
This section provides a real-time view of insider transactions for Longboard Pharmaceuticals, Inc. (LBPH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Longboard Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Longboard Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 02
2024
|
Randall Kaye Executive Vice President & CMO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
30,554
-100.0%
|
$1,833,240
$60.0 P/Share
|
|
Dec 02
2024
|
Kevin Robert Lind President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
363,740
-100.0%
|
$21,824,400
$60.0 P/Share
|
|
Nov 19
2024
|
Randall Kaye Executive Vice President & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,554
+38.66%
|
$183,324
$6.0 P/Share
|
|
Nov 13
2024
|
Kevin Robert Lind President and CEO |
SELL
Bona fide gift
|
Direct |
80,000
-18.03%
|
-
|
|
Nov 13
2024
|
Kevin Robert Lind President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,808
+2.81%
|
$38,424
$3.12 P/Share
|
|
Oct 15
2024
|
Randall Kaye Executive Vice President & CMO |
SELL
Open market or private sale
|
Direct |
16,667
-48.19%
|
$983,353
$59.03 P/Share
|
|
Oct 15
2024
|
Randall Kaye Executive Vice President & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,667
+32.52%
|
$66,668
$4.35 P/Share
|
|
Sep 16
2024
|
Randall Kaye Executive Vice President & CMO |
SELL
Open market or private sale
|
Direct |
16,666
-14.76%
|
$533,312
$32.47 P/Share
|
|
Sep 16
2024
|
Randall Kaye Executive Vice President & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,666
+32.52%
|
$66,664
$4.35 P/Share
|
|
Aug 12
2024
|
Randall Kaye Executive Vice President & CMO |
SELL
Open market or private sale
|
Direct |
16,667
-27.98%
|
$566,678
$34.79 P/Share
|
|
Aug 12
2024
|
Randall Kaye Executive Vice President & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,667
+32.52%
|
$66,668
$4.35 P/Share
|
|
Aug 12
2024
|
Kevin Robert Lind President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
82,482
+8.14%
|
$247,446
$3.66 P/Share
|
|
Jun 25
2024
|
Randall Kaye Executive Vice President & CMO |
SELL
Open market or private sale
|
Indirect |
100
-100.0%
|
$2,000
$20.87 P/Share
|
|
Feb 08
2024
|
Brandi Roberts Executive VP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
15,090
+50.0%
|
-
|
|
Feb 08
2024
|
Randall Kaye Executive Vice President & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
17,920
+50.0%
|
-
|
|
Jan 25
2024
|
Arena Pharmaceuticals Inc |
SELL
Open market or private sale
|
Direct |
3,978,540
-100.0%
|
$95,484,960
$24.25 P/Share
|
|
Jan 23
2024
|
Randall Kaye Executive Vice President & CMO |
BUY
Open market or private purchase
|
Indirect |
100
+50.0%
|
$2,400
$24.82 P/Share
|
|
Mar 16
2021
|
Arena Pharmaceuticals Inc |
BUY
Conversion of derivative security
|
Direct |
138,000
+3.35%
|
-
|